Antibacterial gauze as well as preparation method and application thereof

Abstract

The invention provides antibacterial gauze as well as a preparation method and application thereof, and belongs to the technical field of gauze. The antibacterial gauze comprises two layers of gauze and fibers distributed between the two layers of gauze; the fiber comprises a fiber tube and a filler filled in the fiber tube; the fiber tube comprises a first degradable polymer; the filler comprises a second degradable polymer and an antibacterial agent. The antibacterial gauze provided by the invention comprises the fibers, the fibers comprise the fiber tubes and the filler filled in the fiber tubes, the filler contains the antibacterial medicine, and when the antibacterial gauze is used for binding up a wound, polymers in the fiber tubes and the filler are gradually degraded, so that the antibacterial medicine in the filler is gradually released, and the antibacterial effect is improved. Therefore, the antibacterial time of the gauze is prolonged. The result of the embodiment shows that the release time of the antibacterial medicine in the filler in the antibacterial gauze provided by the invention reaches 28 days, and the antibacterial gauze has a long-term antibacterial effect.

Description

Technical Field

[0001] The invention belongs to the technical field of gauze, and in particular relates to an antibacterial gauze and a preparation method and application thereof. Background Art

[0002] Gauze used clinically is mainly used for wound bandaging in various types of clinical surgeries. Gauze has high permeability, and bacteria can easily invade after being soaked, causing wound infection. Therefore, gauze with antibacterial effect is very necessary.

[0003] In order to improve the antibacterial properties of gauze in the prior art, fibers with antibacterial effects are usually used to make gauze, or antibacterial coatings are applied on the surface of gauze. For example, the invention patent with publication number CN104622640A provides a medical gauze made of chitin fibers with antibacterial and antibacterial effects; and the patent with publication number CN105816904A discloses a medical antibacterial gauze, on the surface of which an antibacterial polypeptide layer is coated. However, although the gauze disclosed in the prior art has an antibacterial effect, its antibacterial time is short, thereby increasing the chance of wound infection during later use. Therefore, there is an urgent need for a gauze with long-term antibacterial function. Summary of the invention

[0004] The purpose of the present invention is to provide an antibacterial gauze and a preparation method and application thereof. The antibacterial gauze provided by the present invention has a long-term antibacterial effect.

[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0006] The present invention provides an antibacterial gauze, comprising two layers of gauze and fibers distributed between the two layers of gauze; the fibers comprise a fiber tube and a filler filled in the fiber tube; the fiber tube comprises a first degradable polymer; the filler comprises a second degradable polymer and an antibacterial drug.

[0007] Preferably, the first degradable polymer and the second degradable polymer independently include one or more of poly(lactic-co-glycolic acid), polylactic acid, polyethylene glycol, polyester, polyhydroxyalkanoate and chitosan.

[0008] Preferably, the inner diameter of the fiber tube is 3-7 mm, and the thickness of the fiber tube is 0.8-3 mm.

[0009] Preferably, the mass ratio of the fiber tube to the filler is (3-5):1.

[0010] Preferably, the mass ratio of the second degradable polymer to the antibacterial drug in the filler is (9-10):1.

[0011] Preferably, the antibacterial drugs include one or more of ciprofloxacin lactate, norfloxacin, penicillins, tetracyclines, fluoroquinolones and chloramphenicol.

[0012] Preferably, the mass ratio of gauze to fiber in the antibacterial gauze is (100-150):1.

[0013] Preferably, the antibacterial gauze further comprises an antibacterial liquid sac; and the antibacterial liquid sac is connected to the fiber.

[0014] The present invention provides a method for preparing the antibacterial gauze described in the above technical solution, comprising the following steps:

[0015] (1) mixing a first degradable polymer and a first solvent and performing a first electrospinning to obtain a fiber tube;

[0016] (2) mixing a second degradable polymer, an antibacterial drug, and a second solvent and performing a second electrospinning to obtain a filler;

[0017] (3) filling the filler obtained in step (2) into the fiber tube obtained in step (1) to obtain fibers;

[0018] (4) distributing the fibers obtained in step (3) between two layers of gauze to obtain antibacterial gauze;

[0019] There is no chronological order for steps (1) and (2).

[0020] The present invention also provides the use of the antibacterial gauze described in the above technical solution or the antibacterial gauze prepared according to the preparation method described in the above technical solution in the preparation of wound dressing products.

[0021] The present invention provides an antibacterial gauze, comprising two layers of gauze and fibers distributed between the two layers of gauze; the fibers include a fiber tube and a filler filled in the fiber tube; the fiber tube includes a first degradable polymer; the filler includes a second degradable polymer and an antibacterial drug. The antibacterial gauze provided by the present invention includes fibers, the fibers include a fiber tube and a filler filled in the fiber tube, the filler contains an antibacterial drug, and when used for wound dressing, the polymers in the fiber tube and the filler gradually degrade, so that the antibacterial drug in the filler is gradually released, thereby extending the antibacterial time of the gauze. The results of the embodiment show that the release time of the antibacterial drug in the antibacterial gauze provided by the present invention reaches 28 days, and has a long-term antibacterial effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 A schematic diagram of the structure of the antibacterial gauze provided by the present invention;

[0023] Figure 2It is a schematic diagram of the structure of the fiber in the antibacterial gauze of the present invention;

[0024] Figure 3 This is the drug release curve of the filler in the fiber of the antibacterial gauze in Example 1 of the present invention. DETAILED DESCRIPTION

[0025] The present invention provides an antibacterial gauze, comprising two layers of gauze and fibers distributed between the two layers of gauze; the fibers comprise a fiber tube and a filler filled in the fiber tube; the fiber tube comprises a first degradable polymer; the filler comprises a second degradable polymer and an antibacterial drug.

[0026] In the present invention, the first and the second have no special meanings and are only used to distinguish between substances.

[0027] The antibacterial gauze provided by the invention comprises two layers of gauze.

[0028] In the present invention, the material and size of the two layers of gauze are preferably the same.

[0029] In the present invention, the gauze is preferably square; the material of the two layers of gauze is preferably pure cotton gauze; the size of each layer of the two layers of gauze is preferably 5cm*5cm*(4-5)mm or 10cm*10cm*(4-5)mm.

[0030] The antibacterial gauze provided by the present invention also includes fibers distributed between two layers of gauze.

[0031] In the present invention, the fiber includes a fiber tube and a filler filled in the fiber tube.

[0032] In the present invention, the fiber tube includes a first degradable polymer; the first degradable polymer preferably includes one or more of polylactic acid-co-glycolic acid PLGA, polylactic acid PLA, polyethylene glycol, polyester, polyhydroxyalkanoate and chitosan, and is more preferably polylactic acid-co-glycolic acid PLGA or polylactic acid PLA. In the present invention, the average molecular weight of the polylactic acid-co-glycolic acid PLGA is preferably 90,000 to 110,000, and more preferably 100,000; the average molecular weight of the polylactic acid PLA is preferably 90,000 to 110,000, and more preferably 100,000. The present invention limits the type of the first degradable polymer to the above range, which is harmless to the human body and can be gradually degraded when used for wound dressing, so that the antibacterial drug in the internal filler is gradually released, and has a more suitable release rate, extending the antibacterial time of the gauze.

[0033] In the present invention, the inner diameter of the fiber tube is preferably 3-7 mm, more preferably 3 mm, 4 mm, 5 mm, 6 mm or 7 mm; the thickness of the fiber tube is preferably 0.8-3 mm, more preferably 1.0-2.0 mm. The present invention limits the inner diameter and thickness of the fiber tube to the above range, which can make the antibacterial drug in the filler have a suitable release rate and further prolong the antibacterial time of the gauze.

[0034] In the present invention, the filler comprises a second degradable polymer and an antibacterial drug.

[0035] In the present invention, the second degradable polymer preferably includes one or more of polylactic acid-co-glycolic acid PLGA, polylactic acid PLA, polyethylene glycol, polyester, polyhydroxyalkanoate and chitosan, and is more preferably polylactic acid-co-glycolic acid PLGA or polylactic acid PLA. In the present invention, the average molecular weight of the polylactic acid-co-glycolic acid PLGA is preferably 90,000 to 110,000, and more preferably 100,000; the average molecular weight of the polylactic acid PLA is preferably 90,000 to 110,000, and more preferably 100,000. The present invention limits the type of the second degradable polymer to the above range, which is harmless to the human body and can be gradually degraded when used for wound dressing, so that the antibacterial drug in the filler is gradually released, and has a more suitable release rate, extending the antibacterial time of the gauze.

[0036] In the present invention, the antibacterial drug preferably includes one or more of ciprofloxacin lactate, norfloxacin, penicillins, tetracyclines, fluoroquinolones and chloramphenicol. In the present invention, the antibacterial drug enables the gauze to have an antibacterial effect.

[0037] In the present invention, the mass ratio of the second degradable polymer to the antibacterial drug in the filler is preferably (9-10): 1, more preferably 10: 1. The present invention limits the mass ratio of the second degradable polymer to the antibacterial drug in the filler to the above range, which can further extend the antibacterial time of the gauze.

[0038] In the present invention, the mass ratio of the fiber tube to the filler is preferably (3-5): 1. The present invention limits the mass ratio of the fiber tube to the filler to the above range, which can further extend the antibacterial time of the gauze.

[0039] In the present invention, the filler is preferably in a spiral shape.

[0040] In the present invention, the mass ratio of gauze to fiber in the antibacterial gauze is preferably (100-150): 1. The present invention limits the mass ratio of gauze to fiber in the antibacterial gauze to the above range, which can further improve the antibacterial effect of the gauze and extend the antibacterial time of the gauze.

[0041] In the present invention, the fibers are preferably evenly distributed between two layers of gauze in a radial shape starting from a corner of the gauze.

[0042] In the present invention, the antibacterial gauze preferably further comprises an antibacterial liquid sac; the antibacterial liquid sac is connected to the fiber.

[0043] In the present invention, the antibacterial liquid in the antibacterial liquid capsule preferably includes one or more of a ciprofloxacin lactate aqueous solution, a norfloxacin aqueous solution, a penicillium aqueous solution, a tetracycline aqueous solution, a fluoroquinolone aqueous solution, and a chloramphenicol aqueous solution. The present invention has no particular limitation on the concentration of the antibacterial liquid, and an antibacterial liquid with an excellent antibacterial effect concentration well known to those skilled in the art can be used.

[0044] In the present invention, the antibacterial liquid in the antibacterial liquid capsule penetrates into the gauze through the fibers, thereby further improving the antibacterial effect of the gauze and extending the antibacterial time of the gauze.

[0045] The present invention has no special restrictions on the material, size, and connection method of the antibacterial liquid capsule with the fiber. Technical solutions well known to those skilled in the art can be used to ensure that the antibacterial liquid can penetrate into the gauze through the fiber.

[0046] In the present invention, the antibacterial liquid capsule preferably includes an antibacterial liquid addition port. The present invention has no special restrictions on the position and size of the antibacterial liquid addition port, and antibacterial liquid can be added to the antibacterial liquid capsule through the antibacterial liquid addition port. The present invention is provided with an antibacterial liquid addition port, so that antibacterial liquid can be added to the antibacterial liquid capsule during use, thereby further extending the antibacterial time of the gauze.

[0047] In the present invention, the structural schematic diagram of the antibacterial gauze containing the antibacterial liquid capsule is preferably as follows Figure 1 shown.

[0048] The present invention provides a method for preparing the antibacterial gauze described in the above technical solution, comprising the following steps:

[0049] (1) mixing a first degradable polymer and a first solvent and performing a first electrospinning to obtain a fiber tube;

[0050] (2) mixing a second degradable polymer, an antibacterial drug, and a second solvent and performing a second electrospinning to obtain a filler;

[0051] (3) filling the filler obtained in step (2) into the fiber tube obtained in step (1) to obtain fibers;

[0052] (4) distributing the fibers obtained in step (3) between two layers of gauze to obtain antibacterial gauze;

[0053] There is no chronological order for steps (1) and (2).

[0054] The present invention mixes a first degradable polymer and a first solvent and then performs first electrostatic spinning to obtain a fiber tube.

[0055] In the present invention, the first solvent preferably includes a mixture of N,N-dimethylformamide and dichloromethane, a mixture of N,N-dimethylformamide and acetone, or a mixture of N,N-dimethylformamide and tetrahydrofuran; the volume ratio of N,N-dimethylformamide to dichloromethane in the mixture of N,N-dimethylformamide and dichloromethane is preferably (0.5-1.5):1, more preferably 1:1; the volume ratio of N,N-dimethylformamide to acetone in the mixture of N,N-dimethylformamide and acetone is preferably (0.5-1.5):1, more preferably 1:1; the volume ratio of N,N-dimethylformamide to tetrahydrofuran in the mixture of N,N-dimethylformamide and tetrahydrofuran is preferably (0.5-1.5):1, more preferably 1:1.

[0056] In the present invention, the mass ratio of the first degradable polymer to the volume ratio of the first solvent is preferably (0.1-0.5) g:10 mL, and more preferably (0.2-0.4) g:10 mL. The present invention limits the type of the first solvent, the mass of the first degradable polymer and the volume ratio of the first solvent to the above range, which is conducive to electrospinning.

[0057] In the present invention, the mixing is preferably carried out under stirring conditions; the stirring time is preferably 1 to 2 hours. The present invention has no particular limitation on the stirring rate, and any stirring rate well known to those skilled in the art can be used.

[0058] In the present invention, the positive voltage of the first electrospinning is preferably 18 to 22 kV, more preferably 20 kV; the negative voltage of the first electrospinning is preferably -0.5 to -2 kV, more preferably -1 kV; the receiving distance of the first electrospinning is preferably 10 to 15 cm, more preferably 12 cm; the receiving device during the first electrospinning is preferably a rolling metal rod. The present invention uses a metal rod as a receiving device, so that a fiber tube is obtained by electrospinning. In the present invention, during the first electrospinning process, the spinning solution obtained by mixing the first degradable polymer and the first solution is electrospun to obtain nanofibers, which are then received by the rolling metal rod to obtain a fiber tube. The present invention limits the parameters of the first electrospinning within the above range, and can obtain nanofibers with uniform thickness.

[0059] After the first electrospinning is completed, the present invention preferably removes the product on the first electrospinning receiving device and dries it to obtain a fiber tube.

[0060] In the present invention, the drying is preferably air-drying. The present invention has no special limitation on the operation of air-drying, and it is sufficient to ensure that the fiber tube is fully dried.

[0061] The present invention mixes a second degradable polymer, an antibacterial drug and a second solvent and then performs second electrostatic spinning to obtain a filler.

[0062] In the present invention, the second solvent preferably includes a mixture of N,N-dimethylformamide and dichloromethane, a mixture of N,N-dimethylformamide and acetone, or a mixture of N,N-dimethylformamide and tetrahydrofuran; the volume ratio of N,N-dimethylformamide to dichloromethane in the mixture of N,N-dimethylformamide and dichloromethane is preferably (0.5-1.5):1, more preferably 1:1; the volume ratio of N,N-dimethylformamide to acetone in the mixture of N,N-dimethylformamide and acetone is preferably (0.5-1.5):1, more preferably 1:1; the volume ratio of N,N-dimethylformamide to tetrahydrofuran in the mixture of N,N-dimethylformamide and tetrahydrofuran is preferably (0.5-1.5):1, more preferably 1:1.

[0063] In the present invention, the mass ratio of the second degradable polymer to the volume ratio of the second solvent is preferably (0.1-0.5) g:10 mL, more preferably (0.2-0.4) g:10 mL. The present invention limits the type of the second solvent, the mass of the second degradable polymer and the volume ratio of the second solvent to the above ranges, which can be beneficial to the electrospinning process.

[0064] In the present invention, the mixing of the second degradable polymer, the antibacterial drug and the second solvent is preferably performed by sequentially adding the second degradable polymer and the antibacterial drug to the second solvent. In the present invention, the mixing is preferably performed under stirring; the stirring time is preferably 1 to 2 hours. The present invention has no particular limitation on the stirring rate, and a stirring rate well known to those skilled in the art can be used.

[0065] In the present invention, the positive voltage of the second electrospinning is preferably 18 to 22 kV, more preferably 20 kV; the negative voltage of the second electrospinning is preferably -0.5 to -2 kV, more preferably -1 kV; the receiving distance of the second electrospinning is preferably 10 to 15 cm, more preferably 12 cm.

[0066] In the present invention, the receiving device during the second electrostatic spinning is preferably a rolling metal rod or metal plate, more preferably a rolling metal rod. In the present invention, the spinning solution obtained by mixing the second degradable polymer, the antibacterial drug and the second solution is electrostatically spun to obtain nanofibers, which are then received by the receiving device. The present invention limits the parameters of the second electrostatic spinning to the above range, and can obtain nanofibers with uniform thickness.

[0067] After the second electrospinning is completed, the present invention preferably removes the product on the second electrospinning receiving device and then dries it to obtain a fiber membrane or a fiber tube.

[0068] In the present invention, the drying is preferably air-drying. The present invention has no special limitation on the operation of air-drying, as long as the fiber is fully dried.

[0069] When the receiving device is a metal plate, the present invention preferably obtains a fiber membrane; when the receiving device is a rolling metal rod, the present invention preferably obtains a fiber tube.

[0070] When the fiber membrane is obtained, the present invention preferably cuts the fiber membrane into pieces to obtain the filler. The present invention has no special limitation on the cutting operation, and the cutting technical solution well known to those skilled in the art can be used to ensure that the filler can be filled into the fiber tube.

[0071] When the fiber tube is obtained, the present invention preferably cuts the fiber tube along the midline and then twists it into a spiral to obtain a filler. The present invention has no special limitation on the operation of cutting the fiber tube along the midline and then twisting it into a spiral. It is sufficient to use a technical solution well known to those skilled in the art to ensure that the spiral filler can be filled into the fiber tube. The present invention uses a spiral filler, which is conducive to inserting into the fiber tube on the one hand; on the other hand, it is more conducive to the sustained release of antibacterial drugs.

[0072] After obtaining the fiber tube and the filler, the present invention fills the filler into the fiber tube to obtain fibers.

[0073] The present invention has no special limitation on the filling operation, and any filling technical solution well known to those skilled in the art may be adopted.

[0074] After obtaining the fibers, the present invention distributes the fibers between two layers of gauze to obtain antibacterial gauze.

[0075] In the present invention, the fiber is preferably pasted between two layers of gauze by glue. The present invention has no special restrictions on the type and amount of the glue, and the glue well known to those skilled in the art is used to ensure that the fiber is pasted between the gauze. In the present invention, the glue is preferably a starch solution with a mass concentration of 5%. In the present invention, the preparation method of the starch solution is preferably: 0.5g of starch is mixed with 10mL of pure water, heated at 100°C for 5min, and cooled to obtain a starch solution.

[0076] When the antibacterial gauze of the present invention includes an antibacterial liquid capsule, the present invention preferably connects the fibers with the antibacterial liquid capsule and then distributes them between two layers of gauze.

[0077] The present invention has no particular limitation on the manner and operation of connecting the fiber and the antibacterial liquid capsule. The two can be connected by a manner and operation well known to those skilled in the art.

[0078] The structural schematic diagram of the fiber prepared by the present invention is preferably as follows Figure 2 As shown, the fiber includes an electrospun nanofiber tube and a spiral electrospun filler filled in the fiber tube.

[0079] The antibacterial gauze prepared by the invention has excellent antibacterial performance and a long antibacterial time.

[0080] The present invention also provides the use of the antibacterial gauze described in the above technical solution or the antibacterial gauze prepared according to the preparation method described in the above technical solution in the preparation of wound dressing products.

[0081] In the present invention, the wound is preferably an in vivo wound. In the present invention, in the in vivo environment, the first degradable polymer and the second degradable polymer in the antibacterial gauze are gradually degraded, and the antibacterial drug is gradually released.

[0082] The present invention has no special limitation on the application, and the technical solutions of the application well known to those skilled in the art may be adopted.

[0083] The technical solutions in the present invention will be described clearly and completely below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0084] Example 1

[0085] An antibacterial gauze, comprising two layers of gauze and fibers distributed between the two layers of gauze; the fibers are composed of a fiber tube and a filler filled in the fiber tube; the fiber tube is PLGA (average molecular weight 100,000); the filler is composed of PLGA (average molecular weight 100,000) and ciprofloxacin lactate; the inner diameter of the fiber tube is 5 mm, and the thickness of the fiber tube is 2 mm; the mass ratio of PLGA to ciprofloxacin lactate in the filler is 10:1; the mass ratio of the fiber tube to the filler is 4:1; the mass ratio of the two layers of gauze to the fibers is 120:1; the material of the gauze is pure cotton gauze; the size of each layer of gauze is 5*5cm*5cm;

[0086] The preparation method of the antibacterial gauze is:

[0087] (1) 0.3 g PLGA and 10 mL of a mixture of N, N-dimethylformamide and dichloromethane (the volume ratio of N, N-dimethylformamide and dichloromethane is 1:1) were mixed under stirring conditions for 1.5 h (the mass ratio of PLGA to the volume ratio of the solvent is 0.3 g:10 mL) to obtain a spinning solution; the electrospinning machine was turned on, preheated for 30 min, the positive voltage was adjusted to 20 kV, the negative voltage was adjusted to -1 kV, and the distance between the nozzle and the spinning receiving was 12 cm; the spinning solution was then sucked into a 20 mL syringe, and a No. 21 needle was used for spinning. A rolling metal rod with a diameter of 0.5 cm was used as an electrospun fiber receiving device. When the nanofibers on the receiver reached a certain thickness, the electrospun nanofiber tube was removed and dried under natural conditions to obtain a fiber tube;

[0088] (2) 0.3 g PLGA, 0.03 g ciprofloxacin lactate and 10 mL N, N-dimethylformamide and dichloromethane (the volume ratio of N, N-dimethylformamide and dichloromethane is 1:1) were mixed under stirring conditions for 1.5 h (the mass ratio of PLGA to the volume of the solvent was 0.3 g:10 mL, and the mass ratio of PLGA to ciprofloxacin lactate was 10:1) to obtain a spinning solution; the electrospinning machine was turned on, preheated for 30 min, the positive voltage was adjusted to 20 kV, the negative voltage was -1 kV, and the nozzle and spinning receiving distance was 12 cm; then the spinning solution was sucked into a 20 mL syringe, and a No. 21 needle was used for spinning. A rolling metal rod with a diameter of 0.5 cm was used as an electrospun fiber receiving device. When the nanofibers on the receiver reached a thickness of 2 mm, the electrospun nanofiber tube was removed and dried under natural conditions, cut along the center line of the fiber tube and twisted into a spiral to obtain a filler;

[0089] (3) inserting the filler in step (2) into the fiber tube in step (1) to obtain fibers;

[0090] (4) Take two layers of gauze, spread the fibers prepared in step (3) radially and uniformly between the two layers of gauze from one corner of the gauze, and paste them with a starch solution having a mass concentration of 5% to obtain an antibacterial gauze.

[0091] Example 2

[0092] The PLGA in the fiber tube and the filler of Example 1 was replaced by polylactic acid PLA (average molecular weight 100000), and the other parameters were the same as those in Example 1.

[0093] Antibacterial performance test: In a clean bench, use a sterile cotton swab to scrape Staphylococcus aureus and Escherichia coli colonies into a sterile sodium chloride-peptone solution with a pH value of 7.0, and use 6*10 8 cfu / mL, and then conduct gradient dilution to reach the final bacterial solution concentration of 6*10 5 cfu / mL, and then a sterile cotton swab was used to collect 6*10 5 cfu / mL solution was evenly spread on a tryptic soy agar culture dish; samples with a diameter of 5 mm were cut from the fiber prepared in step (3) of Example 1 and the antibacterial gauze prepared in step (4) of Example 1, and gently pressed into the culture dish smeared with bacteria. The dish was covered and placed in an incubator for overnight culture. The diameter of the inhibition ring was observed. The results are shown in Tables 1 and 2.

[0094] Table 1 Antibacterial properties of the fibers prepared in step (3) of Example 1

[0095] Diameter of antibacterial ring (mm) Staphylococcus aureus 8.35 Escherichia coli 7.99

[0096] Table 2 Antibacterial properties of the antibacterial gauze prepared in step (4) of Example 1

[0097] Diameter of antibacterial ring (mm) Staphylococcus aureus 7.47 Escherichia coli 7.84

[0098] It can be seen from Tables 1-2 that the fiber and antibacterial gauze prepared in Example 1 both have excellent antibacterial properties.

[0099] The same method was used to test the antibacterial properties of the antibacterial gauze in Example 1 and Example 2 at the beginning and 28 days, respectively. The results are shown in Table 3.

[0100] Table 3 Antibacterial properties of antibacterial gauze in Example 1 and Example 2 at the beginning and 28 days

[0101]

[0102]

[0103] As can be seen from Table 3, the antibacterial properties of the antibacterial gauze in Examples 1 and 2 can reach 28 days.

[0104] 0.1 g of the filler prepared in step (2) of Example 1 was accurately weighed and placed in a 1.5 mL EP tube at room temperature. 1 mL PBS buffer (pH = 7.4) was added for soaking. Starting from the first day, 200 μL of the PBS buffer after soaking was quantitatively taken every day for concentration measurement. At the same time, the same amount of fresh PBS buffer was added to the EP tube to test the drug release curve of the filler. The results are shown in FIG. Figure 3 As shown. Figure 3 It can be seen that the drug release amounts of the filler at 1, 3, 5, 7, 14 and 28 days are 2.087 mg, 2.998 mg, 3.401 mg, 3.799 mg, 4.133 mg and 7.534 mg respectively. The filler prepared by the present invention has a good sustained-release effect, so that the gauze can have a long-term antibacterial effect, and the antibacterial effect can reach 28 days.

[0105] In summary, the antibacterial gauze provided by the present invention has excellent antibacterial effect and a long antibacterial time.

[0106] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. An antibacterial gauze, comprising two layers of gauze and fibers distributed between the two layers of gauze; the fibers comprise a fiber tube and a filler filled in the fiber tube; the fiber tube comprises a first degradable polymer; the filler comprises a second degradable polymer and an antibacterial drug.

2. The antibacterial gauze according to claim 1, characterized in that: The first degradable polymer and the second degradable polymer independently include one or more of poly(lactic-co-glycolic acid), polylactic acid, polyethylene glycol, polyester, polyhydroxyalkanoate and chitosan.

3. The antibacterial gauze according to claim 1, characterized in that: The inner diameter of the fiber tube is 3-7 mm, and the thickness of the fiber tube is 0.8-3 mm.

4. The antibacterial gauze according to claim 1, characterized in that: The mass ratio of the fiber tube to the filler is (3-5):

1.

5. The antibacterial gauze according to claim 1, characterized in that: The mass ratio of the second degradable polymer to the antibacterial drug in the filler is (9-10):

1.

6. The antibacterial gauze according to claim 1, characterized in that: The antibacterial drugs include one or more of ciprofloxacin lactate, norfloxacin, penicillins, tetracyclines, fluoroquinolones and chloramphenicol.

7. The antibacterial gauze according to claim 1, characterized in that: The mass ratio of gauze to fiber in the antibacterial gauze is (100-150):

1.

8. The antibacterial gauze according to claim 1, characterized in that: The antibacterial gauze also includes an antibacterial liquid sac; the antibacterial liquid sac is connected to the fiber.

9. The method for preparing the antibacterial gauze according to any one of claims 1 to 8, comprising the following steps: (1) mixing a first degradable polymer and a first solvent and performing a first electrospinning to obtain a fiber tube; (2) mixing a second degradable polymer, an antibacterial drug, and a second solvent and performing a second electrospinning to obtain a filler; (3) filling the filler obtained in step (2) into the fiber tube obtained in step (1) to obtain fibers; (4) distributing the fibers obtained in step (3) between two layers of gauze to obtain antibacterial gauze; There is no chronological order for steps (1) and (2).

10. Use of the antibacterial gauze according to any one of claims 1 to 8 or the antibacterial gauze prepared according to the preparation method according to claim 9 in the preparation of wound dressing products.

Images